Stent thrombosis (ST) has complicated coronary artery

Size: px
Start display at page:

Download "Stent thrombosis (ST) has complicated coronary artery"

Transcription

1 Interventional Cardiology Incomplete Stent Apposition and Very Late Stent Thrombosis After Drug-Eluting Stent Implantation Stéphane Cook, MD; Peter Wenaweser, MD; Mario Togni, MD; Michael Billinger, MD; Cyrill Morger, MD; Christian Seiler, MD; Rolf Vogel, MD, PhD; Otto Hess, MD; Bernhard Meier, MD; Stephan Windecker, MD Background Stent thrombosis may occur late after drug-eluting stent (DES) implantation, and its cause remains unknown. The present study investigated differences of the stented segment between patients with and without very late stent thrombosis with the use of intravascular ultrasound. Methods and Results Since January 2004, patients presenting with very late stent thrombosis ( 1 year) after DES implantation underwent intravascular ultrasound. Findings in patients with very late stent thrombosis were compared with intravascular ultrasound routinely obtained 8 months after DES implantation in 144 control patients, who did not experience stent thrombosis for 2 years. Very late stent thrombosis was encountered in 13 patients at a mean of days after DES implantation. Compared with DES controls, patients with very late stent thrombosis had longer lesions ( versus mm; P 0.001) and stents ( versus mm; P 0.001), more stents per lesion ( versus ; P 0.001), and stent overlap (39% versus 8%; P 0.001). Vessel cross-sectional area was similar for the reference segment (cross-sectional area of the external elastic membrane: versus mm 2 ; P 0.46) but significantly larger for the in-stent segment ( versus mm 2 ; P 0.03) in very late stent thrombosis patients compared with DES controls. Incomplete stent apposition was more frequent (77% versus 12%; P 0.001) and maximal incomplete stent apposition area was larger ( versus mm 2 ; P 0.03) in patients with very late stent thrombosis compared with controls. Conclusions Incomplete stent apposition is highly prevalent in patients with very late stent thrombosis after DES implantation, suggesting a role in the pathogenesis of this adverse event. (Circulation. 2007;115: ) Key Words: coronary disease imaging patients stents ultrasonics Stent thrombosis (ST) has complicated coronary artery stent implantation since its inception and is associated with considerable morbidity and mortality due to abrupt vessel closure. 1,2 Several case reports and observational studies suggest that ST may occur unusually late in patients treated with drug-eluting stents (DES), a phenomenon referred to as very late ST. 3,4 Recent investigations have reported variables consistently associated with ST after DES implantation, such as discontinuation of antiplatelet therapy, brachytherapy, bifurcation stenting, acute coronary syndromes, renal insufficiency, and diabetes. 2,5 Furthermore, hypersensitivity reactions and localized inflammation have been identified in autopsy-proven ST cases. 6,7 However, the cause of very late ST and the underlying changes in arterial structure are largely unknown. Intravascular ultrasound (IVUS) identifies mechanisms of stent failure by providing complementary information regarding the extent and distribution of neointima, arterial remodeling, stent underexpansion, and incomplete stent apposition (ISA). 8 IVUS studies in patients suffering from early ( 30 Editorial p 2379 Clinical Perspective p 2434 days) ST after bare metal stent (BMS) 9 and DES implantation 10 found stent underexpansion and residual stenoses as predisposing factors. However, no study examined structural differences in stented vessel segments in patients with very late ST ( 1 year) after DES implantation. We therefore performed IVUS imaging before emergency percutaneous coronary intervention (PCI) in patients presenting with very late ST after DES implantation. These findings were compared with IVUS routinely obtained 8 months after DES implantation in 144 control patients, who did not experience ST within 2 years of follow-up, in an attempt to identify structural changes in the stented vessel segment associated with very late ST. Methods Patients Nineteen patients presented with very late ST ( 1 year) after DES implantation at our institution (Figure 1). Since January 2004, a Received August 14, 2006; accepted February 20, From the Department of Cardiology, University Hospital Bern, Bern, Switzerland. Correspondence to Stephan Windecker, MD, Department of Cardiology, University Hospital Bern, 3010 Bern, Switzerland. stephan.windecker@insel.ch 2007 American Heart Association, Inc. Circulation is available at DOI: /CIRCULATIONAHA

2 Cook et al Incomplete Stent Apposition and Stent Thrombosis 2427 Figure 1. Stent availability (A) and time distribution of very late ST (B) at the University Hospital Bern. Between April 2002 and December 2005, 2775 patients were treated with SES, and between March 2003 and April 2005, 1365 patients were treated with PES. Nineteen patients suffered from very late ST between April 2003 and December Since January 2004, we performed systematic IVUS before emergency PCI in 13 patients, who constitute the study population of the present report. protocol was implemented to perform IVUS before emergency PCI in patients presenting with very late ST. Thus far, 13 patients were investigated and represent the study population of this report. Control patients constituted a subpopulation of the SIRTAX (Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization) trial, 11 in which IVUS was performed routinely at the time of follow-up angiography (8 months after DES implantation) in the first 236 enrolled subjects. After exclusion of patients who underwent IVUS at another institution, those who had suffered from ST during the 2-year follow-up period, and segments with failed acquisition, volumetric analysis was possible in 144 patients with 175 stented segments. IVUS control patients were monitored prospectively for 2 years with documentation of the absence of any clinical adverse event during this observation period. The study complied with the Declaration of Helsinki regarding investigation in humans and was approved by the ethics committee at the University Hospital Bern in Switzerland. All patients provided written informed consent. Drug-Eluting Stents DES availability at our institution is summarized in Figure 1. Sirolimus-eluting stents (SES) (Cypher, Cordis, a Johnson & Johnson Company, Miami Lakes, Fla) became available in April 2002, followed by paclitaxel-eluting stents (PES) (Taxus, Boston Scientific) in March From April 2003 to May 2004, both DES were used in a randomized clinical trial. 11 This was followed by use of both DES on an alternating basis until April 2005, at which time the use of PES was abandoned. Definition of ST Timing of ST was categorized as very late when occurring 1 year after DES implantation. Only patients presenting with very late ST were included in the present study. ST was defined as the association of clinical symptoms with angiographic confirmation of thrombotic stent occlusion. Clinical signs and symptoms were considered to be present if at least 1 of the following criteria was met: (1) sudden onset of typical chest pain with duration 20 minutes; (2) ischemic ECG changes; (3) typical rise and fall of cardiac biomarkers. Angiographic criteria for ST were fulfilled when the Thrombolysis in Myocardial Infarction flow was (1) grade 0 with occlusion originating in the persistent region or (2) grade 1, 2, or 3 in the presence of a thrombus originating in the persistent region. Quantitative Coronary Angiographic Analysis Coronary angiograms were recorded digitally at baseline, after the procedure, and at follow-up and were assessed at the angiographic core laboratory of the University Hospital Bern. Angiograms were analyzed by personnel unaware of patient group or type of stent implanted. Digital angiograms were analyzed with the use of an automated edge-detection system (CAAS II, Pie Medical Imaging, Maastricht, the Netherlands). Quantitative measurements included diameter of the reference vessel, minimal luminal diameter, and extent of stenosis (defined as diameter of the reference vessel minus minimal luminal diameter, divided by reference diameter, and multiplied by 100). IVUS Image Acquisition and Analysis The protocol sequence to obtain IVUS is depicted in Figure 2A. In very late ST patients, IVUS was obtained in the affected stent segment before emergency PCI. First, intracoronary nitroglycerin was administered, and an angiogram with the use of a 6F guiding catheter was performed to define the site of thrombotic stent occlusion. Then a inch coronary guidewire was passed through the affected stent, followed by advancement of the IVUS catheter (EagleEye, Volcano Therapeutics, Inc, Cordova, Calif) 10 mm beyond the distal edge of the affected stent. The IVUS catheter was withdrawn with the use of motorized pullback (0.5 mm/s), and images were recorded continuously throughout the stent and at least 10 mm distal and proximal to the stent. Then the imaging catheter was withdrawn, and PCI with the use of standard techniques was begun. IVUS was repeated at the end of the procedure. All IVUS procedures were recorded digitally on CD-ROM. Quantitative IVUS analyses were performed offline with computerized planimetry (In-VisionView 1.0, Medimatic Inc) (Figure 2B). Quantitative measures included the external elastic membrane (EEM) (mm 2 ), lumen cross-sectional area (CSA) (mm 2 ), and stent CSA (mm 2 ) at stented and reference segments. The image slice with the smallest stent CSA and lumen CSA and the image slice with the greatest EEM were also analyzed. Minimal stent CSA (mm 2 ) was measured at the site of the smallest stent diameter through the center point of the stent. The proximal and distal reference segments selected for analysis were the most normal-looking cross sections within 10 mm proximal or distal to the lesion but before any side branch. ISA was defined as lack of contact between at least 1 strut and the underlying arterial wall intima that did not overlap a side branch with evidence of blood flow behind the strut (Figure 2C). 12,13 Stent expansion index was defined as the ratio of minimal stent CSA divided by the mean proximal and distal reference lumen areas. Stent underexpansion was defined as stent expansion 80% (stent expansion index 0.80). 9 Neointima was calculated as stent minus lumen CSA

3 2428 Circulation May 8, 2007 Figure 2. The protocol sequence of IVUS imaging in very late ST patients is depicted in A, as follows: (1) After administration of nitroglycerin (0.2 mg), an angiogram with the use of a 6F guiding catheter was performed to define the site of thrombotic stent occlusion. (2) A inch coronary guidewire was passed through the affected stent. (3) A commercially available IVUS catheter (EagleEye scanner, Volcano Therapeutics, Inc) was advanced 10 mm beyond the distal edge of the affected stent. The IVUS catheter was withdrawn with the use of a motorized pullback (0.5 mm/s), and images were recorded continuously throughout the stent and at least 10 mm distal and proximal to the stent. (4), (5) After IVUS images were obtained, the imaging catheter was withdrawn, and PCI with the use of standard techniques was begun. (6) IVUS acquisition was repeated after successful PCI. B, Images were analyzed offline. With the use of computerized planimetry (In-VisionView 1.0, Medimatic Inc), the stent and reference segments were analyzed. The EEM, the lumen, and the stent CSA were measured every 2 mm within the stent segment, and CSA measurements represent the average of all measurements. Minimal stent CSA (mm 2 ) was measured at the site of the smallest stent diameter through the center point of the stent. The proximal and distal reference segments were analyzed every millimeter. C, Example of ISA with lack of contact between at least 1 strut and the underlying arterial wall intima. measures. Coronary aneurysm was defined as a maximum lumen area 50% larger than the proximal reference lumen area. Statistical Analysis Continuous data are expressed as mean SD. Continuous data were compared with the use of an unpaired t test if the data were normally distributed; otherwise, a Mann-Whitney U test was used. Categorical data are presented as frequencies and were compared by 2 statistics. A 2-tailed probability value 0.05 was considered statistically significant. All statistical analyses were performed with SPSS software The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written. Results Baseline Clinical and Angiographic Characteristics Baseline clinical characteristics were similar in patients with very late ST and DES controls (Table 1). The indication for the PCI at the time of the index procedure was an acute ST-segment elevation myocardial infarction in 46% of very late ST patients and in 26% of DES controls (P 0.17). Baseline angiographic characteristics showed significant differences between very late ST patients and DES controls with respect to lesion length ( versus ; P 0.001), stent length ( versus mm; P 0.001), number of stents per lesion ( versus ; P 0.001), and rate of overlapping stents (39% versus 8%; P 0.001) (Table 2). In contrast, lesion site, DES type, reference vessel diameter, stent diameter, and angiographic results at the end of the procedure were comparable for both groups. Very Late ST A total of 13 patients suffered very late ST (8 patients with SES, 5 with PES), with detailed information of individual TABLE 1. Baseline Clinical Characteristics Very Late ST DES Control P No. of patients Age, mean SD, y Male sex 13 (100) 114 (79) 0.08 Diabetes mellitus 0 (0) 26 (18) 0.13 Hypertension 8 (62) 78 (54) 0.77 Dyslipidemia 8 (62) 80 (56) 0.78 Current smoking 5 (39) 59 (41) 0.86 Stable angina pectoris 4 (31) 72 (50) 0.25 Acute coronary syndromes 9 (69) 72 (50) 0.25 STEMI 6 (46) 37 (26) 0.17 Non-STEMI 3 (23) 35 (24) 0.60 Glycoprotein IIb/IIIa antagonists 5 (39) 38 (26) 0.34 Multivessel disease 6 (46) 82 (57) 0.56 Left ventricular ejection fraction, % SD Values are expressed as n (%) unless otherwise indicated. STEMI indicates ST-segment elevation myocardial infarction.

4 Cook et al Incomplete Stent Apposition and Stent Thrombosis 2429 TABLE 2. TABLE 3. Pt No. Age, y Baseline Angiographic Characteristics Very Late ST DES Control P No. of segments Target lesion coronary artery, n (%) Left anterior descending 6 (46) 72 (41) 0.50 Left circumflex 1 (8) 37 (21) 0.50 Right 6 (46) 66 (38) 0.50 DES stent type, n (%) SES 8 (62) 86 (49) 0.57 PES 5 (39) 89 (51) 0.57 Before procedure Lesion length, mm Reference vessel diameter, mm Minimal lumen diameter, mm Stenosis, % lumen diameter During procedure Stents per lesion, n Stent diameter, mm Stent length, mm Maximal pressure, atm Stent overlap, n (%) 5 (39) 14 (8) After procedure Final minimal lumen diameter, mm In-stent In-segment Final stenosis, % of lumen diameter In-stent In-segment Values are mean SD unless indicated otherwise. Findings in 13 Patients With Very Late ST Sex Indication for PCI at Index Procedure Risk Factors Target Vessel Days After Procedure patients regarding time, DES type, antiplatelet therapy, and IVUS findings provided in Table 3. Very late ST occurred at a mean of days after the index procedure (Figure 1). All very late ST patients underwent IVUS before emergency PCI. The DES control patient population were all free of adverse events at a mean follow-up of days (P 0.05 versus mean follow-up of very late ST patients). IVUS Findings Quantitative IVUS analysis was possible in all segments (n 13 for very late ST patients; n 175 segment in 144 DES control patients), and data are summarized in Table 4. Vessel CSA was comparable for the reference segment (EEM CSA: versus mm 2 ; P 0.46) but significantly larger for the in-stent segment (EEM CSA: versus mm 2 ; P 0.03) in patients with very late ST compared with DES controls (Figure 3). Incomplete stent apposition was present in 10 very late ST patients (77%) compared with 21 DES controls (12%) (P 0.001), and maximal ISA area was larger in very late ST patients compared with DES controls ( versus mm 2 ; P 0.03) (Figure 4A and 4B). ISA foci were located at the proximal stent segment in 36%, at the stent body in 45%, and at the distal stent segment in 18% of cases. Although stent CSA ( versus mm 2 ; P 0.83) and minimal stent CSA were similar ( versus mm 2 ; P 0.90), 2 of 13 very late ST lesions (15%) had a minimal stent CSA 4.0 mm 2 compared with 9 of 175 control lesions (5%) (P 0.13). Stent expansion index was reduced in very late ST patients compared with DES controls ( versus ; P 0.04). In 4 of 13 very late ST patients (31%), stent underexpansion was related to a circumferential calcium ring (arc 360 ) (Figure 4C). Stent expansion was inversely related to stent length (R , P 0.001), and Type of DES Antiplatelet Therapy Stent Expansion Index Minimal Stent CSA, mm 2 Maximal ISA CSA, mm 2 Supplemental IVUS Findings 1 61 M Stable angina pectoris, CCS II Hypertension, LCX 871 SES Aspirin ISA, calcium arc M Stable angina pectoris, CCS III Hypertension, LAD 551 PES Aspirin M STEMI inferior Smoking RCA 660 PES Aspirin ISA, long stented segment 4 61 M Stable angina pectoris, CCS II Hypertension, LAD 646 SES Aspirin Calcium arc M Non-STEMI Hypertension, 6 80 M Non-STEMI Hypertension, 7 69 M Unstable angina, Braunwald class III B Hypertension,, smoking RCA 585 SES Aspirin, clopidogrel ISA, Calcium arc 360, long stented segment LAD 469 SES Aspirin ISA, calcium arc 360 RCA 925 SES None* ISA, aneurysm 8 43 M Non-STEMI Hypertension, smoking RCA 442 PES Aspirin ISA 9 54 M STEMI anterior Smoking LAD 705 SES None* ISA, aneurysm, long stented segment M STEMI anterior None LAD 565 SES Aspirin, oral ISA anticoagulation M STEMI anterior Smoking LAD 584 SES Aspirin ISA, aneurysm M STEMI inferior Hypertension, RCA 823 PES Aspirin ISA M STEMI inferior Smoking RCA 370 PES None* In-stent restenosis CCS indicates Canadian Cardiovascular Society; LCX, left circumflex; LAD, left anterior descending; STEMI, ST-segment elevation myocardial infarction; and RCA, right coronary artery. *Patients interrupted antiplatelet therapy in the context of a surgical procedure.

5 2430 Circulation May 8, 2007 TABLE 4. IVUS Measurements Very Late ST DES Control P No. of segments Reference segment EEM CSA, mm Lumen CSA, mm Stent segment EEM CSA, mm Stent CSA, mm Minimal stent CSA, mm Minimal stent CSA 4 mm 2, n (%) 2 (15%) 9 (5%) 0.13 Stent expansion Overlapping stents Nonoverlapping stents In-stent lumen CSA, mm Neointimal hyperplasia, mm ISA, n (%) 10 (77) 21 (12) Maximal ISA CSA, mm Maximal ISA length, mm Maximal ISA depth, mm Location, % Proximal stent segment Stent body Distal stent segment Values expressed as mean SD unless otherwise indicated. overlapping stents were less well expanded than nonoverlapping stents (very late ST group, versus ; P 0.42; control group, versus ; P 0.02). Discussion The present study demonstrates that patients with very late ST show evidence of positive arterial remodeling with a high Figure 3. Mean value ( SD) of EEM CSA in the proximal reference segment, stent segment, and distal reference segment in patients with very late ST (black; n 13) and DES controls (white; n 175). incidence of ISA. This is especially apparent when these patients are compared with DES controls. Incomplete Stent Apposition ISA is defined as separation of stent struts from the arterial wall with evidence of blood flow behind the strut in the absence of a bifurcation. 12,14 Late acquired ISA has been observed in 2% to 5% of patients treated with BMS. 15,16 Most IVUS studies of DES thus far have investigated SES and PES, the 2 DES stent types also employed in the present study, and ISA has been reported in 7% to 21% of these patients. 17,18 Several mechanisms of ISA have been proposed and are depicted schematically in Figure 5, as follows: (1) positive arterial remodeling with an increase of EEM out of proportion to the increase in persistent plaque and media; (2) a decrease in plaque and media due to dissolution of jailed thrombus or plaque debris, ie, patients undergoing stent implantation during acute myocardial infarction; (3) ISA not recognized at implantation and detected at follow-up (persistent ISA); this may be mediated in part by severely calcified lesions not allowing for homogeneous stent expansion and resulting in stent underexpansion (lever principle); and (4) chronic stent recoil without any change in arterial dimensions (not illustrated). To differentiate late acquired from persistent ISA, IVUS imaging is required both at the end of the index procedure and at follow-up. The omission of postprocedural IVUS imaging is an important limitation of the present study, in which IVUS was performed only at the time of very late ST or 8 months after DES implantation in the control group. Therefore, it was not possible to discern chronic stent recoil and persistent ISA from the other mechanisms responsible for late ISA. However, previous studies with tubular slotted stents have shown the absence of any significant stent recoil, rendering this mechanism of ISA unlikely in this study. 19 In addition, the incidence of ISA in the DES control group (12%) was similar to the rates reported by other investigators in recent IVUS studies with DES, 17,20,21 in which regional remodeling was identified as the prevailing mechanism of late ISA. Accordingly, ISA due to positive arterial remodeling with an increase of the EEM out of proportion to changes in plaque and media appears to be the most likely mechanism of ISA in the present study. Because a considerable portion of patients presented with an acute coronary syndrome at the time of the index procedure, the decrease of plaque with dissolution of jailed thrombus may have been another important mechanism of ISA in our patient population. The proportion of patients with ST-segment elevation myocardial infarction was (nonsignificantly) higher in the very late ST group than in controls, and long-term follow-up from prospective randomized trials comparing DES with BMS in the setting of acute myocardial infarction will determine whether the use of DES is associated with an increased risk of very late ST in this patient population. Recently, Feres and colleagues 22 described 2 patients with very late ST after DES implantation in whom serial angiographic and IVUS imaging were available for de-

6 Cook et al Incomplete Stent Apposition and Stent Thrombosis 2431 Figure 4. IVUS findings in patients presenting with very late ST. A, Patient (patient 1) received 1 BMS (BMS 1) in the proximal circumflex artery and 1 SES (SES 2) in the first obtuse marginal branch during the index procedure (top right). Eight hundred seventyone days after PCI, the patient presented with very late ST and thrombotic occlusion of the SES but not the BMS (top left). The EEM is considerably larger in the persistent area of SES (2) as opposed to the BMS (1), and incomplete stent apposition (*) is easily apparent. Prox indicates proximal; dist, distal. B, Example of very late ST occurring 925 days after PCI (patient 7) (angiography, top left). The proximal segment of the right coronary artery has been treated with a BMS, whereas the distal lesion was treated with a SES at the time of the index procedure (angiography, bottom left). The IVUS longitudinal view shows the BMS proximally and the SES distally. The EEM is markedly increased at the vicinity of the SES but not the BMS, which again is associated with ISA (arrows). The BMS shows evidence of mild in-stent restenosis (ISR). C, Example of very late ST occurring 469 days (patient 6) after implantation of a single SES implanted in the left anterior descending artery (angiography, top right: result at the time of the index procedure; angiography, top left: thrombotic stent occlusion). The stent dimension is shown as a gray box in the longitudinal IVUS view. The stent is expanded poorly, as indicated by a minimal CSA of only 3.5 mm 2 distally. The likely mechanism for stent underexpansion is the presence of a heavily calcified lesion with a circumferential calcium arc (fulcrum). The stent is not malapposed (ISA) at the actual site of calcification but rather in its vicinity. It is noteworthy that whereas calcium may be the cause of stent underexpansion, a soft lesion is rather the cause of ISA.

7 2432 Circulation May 8, 2007 Figure 5. Mechanisms leading to incomplete stent apposition. I, Positive arterial remodeling with an increase of EEM out of proportion to the increase in persistent plaque and media, which leads to ISA (B) of an initially well-apposed stent (A). II, A decrease in plaque due to dissolution of jailed material, ie, patients undergoing stent implantation during acute myocardial infarction. A, Completely apposed stent with thrombus jailed behind the struts. B, ISA during follow-up due to thrombolysis. III, ISA not recognized at implantation and detected at follow-up (persistent ISA). This may be mediated in part by severely calcified lesions not allowing for homogeneous stent expansion. Thus, a site of calcification (fulcrum) may result in localized underexpansion of the stent and ISA (lever principle) at its vicinity due to either insufficient balloon pressure or inability to overcome the inherent stiffness of the stent structure (B). tailed analysis. These investigators observed late acquired ISA with pronounced positive arterial remodeling within the stented segment, suggesting a causal link between the vascular response to DES implantation and very late ST in certain patients. Virmani et al 6 described a local hypersensitivity reaction with extensive vasculitis of the intima, media, and adventitia consisting predominantly of lymphocytes and eosinophils in a patient suffering from very late ST (18 months) after DES implantation. Histopathological analysis revealed an aneurysmal dilatation of the vessel wall within the stented segment with evidence of stent malapposition and thick fibrin thrombus between the stent and the arterial wall. Chronic inflammation with outward remodeling of the arterial wall in response to DES implantation has been confirmed as one of the mechanisms of ST in a larger pathological series from the same laboratory, 7 and clinical evidence of hypersensitivity reactions stems from the Research on Adverse Drug Events and Reports project (RADAR) registry, 23 in which 17 of 5783 cases were probably or certainly related to DES. In the retrospective Predictors and Outcomes of Stent Thrombosis (POST) registry, 9 ISA was observed in 49% of 53 patients with early ST ( 30 days) after BMS implantation. Subsequent IVUS studies with BMS 24 and DES 17,20,21 failed to identify late ISA as a predictor of clinical adverse events. However, the predictive accuracy of these studies may have been limited by the small number of patients with late ISA (13 to 90 patients), the limited follow-up period of only 12 months in patients after DES implantation, and the infrequent occurrence of very late ST in stent patients. The approach in the present study was different in that we focused on the rare patient presenting with very late ST (13 of 4140 DES patients) and performed IVUS before emergency PCI. The finding of ISA in more than three quarters of patients (77%) with very late ST contrasts with an incidence of only 12% in the DES control group, suggesting a role in the pathogenesis of this adverse event. In addition, the extent of ISA, in terms of both length and depth, was more pronounced in very late ST patients than in controls. This finding suggests that small areas of ISA may be clinically silent, whereas large areas of ISA may increase the risk of ST. Interestingly, 2 patients with very late ST had a BMS implanted in addition to a DES in the same vessel during the index procedure. In both patients, EEM CSA was considerably enlarged in the vicinity of the DES but not in the BMS (Figure 4), and ST was limited to the DES segment with no thrombus present in the BMS. The mechanism by which ISA may contribute to ST remains speculative. It has been postulated that ISA may serve as a local nidus for thrombus formation by allowing for fibrin and platelet deposition. 25 Thus, ISA may be the consequence of chronic inflammation and delayed healing, resulting in tissue necrosis and erosion around the stent. 7 In addition, the positive remodeling of the arterial wall reduces blood flow between the aneurysmatic wall and the stent struts. Finally, ISA may be only a marker for other mechanisms primarily causing ST such as delayed reendothelialization, impaired vasomotion, and chronic inflammation, which allow for platelet adhesion, initiation of the coagulation cascade, and subsequent thrombotic stent occlusion. Other Ultrasonic Predictors of ST Ultrasonic predictors of early ST after BMS implantation were stent underexpansion, residual dissections, and thrombus. 9,13 In a recent study of 21 patients with documented SES thrombosis occurring an average of 14 days after the index procedure, Fujii and colleagues 10 identified stent underexpansion and a residual reference segment stenosis as predictors of early ST. In the present study, 4 very late ST patients also had evidence of stent underexpansion, which was related to severely calcified lesions with a calcium arc of 360. Although stent CSA and minimal stent CSA were similar between very late ST patients and DES controls in the present study, stent expansion was reduced in the former, reflecting the some-

8 Cook et al Incomplete Stent Apposition and Stent Thrombosis 2433 what larger reference lumen CSA in this group. Stent expansion may have been related to inappropriate stent deployment at the time of the index procedure. Alternatively, positive remodeling of the reference segments caused by the drug-polymer combination may have led to the false impression of stent underexpansion, whereas the vessel only outgrew the originally appropriately sized stent. Two patient populations emerged from the present study. The majority of patients with very late ST showed evidence of vessel remodeling with or without aneurysm formation associated with predominantly large areas of ISA covering a long segment of the stent length, suggesting a dynamic biological process possibly related to chronic inflammation within the arterial wall. In contrast, another group was characterized predominantly by stent underexpansion with or without only small areas of ISA and/or restenosis, suggesting rather mechanical factors and inadequate stent implantation as factors contributing to ST. Limitations Several limitations require consideration when the results of the present study are interpreted. The most important limitation is the lack of a reference IVUS examination at the end of the index procedure and therefore the inability to differentiate between persistent and late acquired ISA. The control group underwent routine IVUS imaging at 8 months, and subsequent clinical follow-up was uneventful up to 2 years after DES implantation. However, it cannot be excluded that IVUS results might have changed during extended follow-up. Given the size of the control group and the extent of differences between both patient populations, it is unlikely that results would have changed considerably. Moreover, IVUS results of the very late ST group were acquired at the time of stent thrombosis and may have been different if IVUS had been performed at an earlier time point. Accordingly, the predictive value of the presence or absence of ISA during follow-up IVUS examinations remains unknown. Furthermore, the results of the present study apply only to patients with very late ST after DES implantation, whereas early ST may be associated with other or additional factors. Finally, the number of patients with very late ST was small, and therefore it was not the purpose of this study to address other clinical predictors of ST. Conclusion ISA is highly prevalent in patients with very late ST after DES implantation, suggesting a role in the pathogenesis of this adverse event. Positive arterial remodeling appears as the most likely mechanism of ISA in the present study. Sources of Funding The present study was supported by a research grant from the University Hospital Bern, Bern, Switzerland. There was no industry involvement in the design, conduct, or analysis of the study. None. Disclosures References 1. Wenaweser P, Rey C, Eberli FR, Togni M, Tuller D, Locher S, Remondino A, Seiler C, Hess OM, Meier B, Windecker S. Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome. Eur Heart J. 2005;26: Kuchulakanti PK, Chu WW, Torguson R, Ohlmann P, Rha SW, Clavijo LC, Kim SW, Bui A, Gevorkian N, Xue Z, Smith K, Fournadjieva J, Suddath WO, Satler LF, Pichard AD, Kent KM, Waksman R. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation. 2006;113: McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, Suddath WO, Weissman NJ, Torguson R, Kent KM, Pichard AD, Satler LF, Waksman R, Serruys PW. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364: Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis events with drugeluting stents. J Am Coll Cardiol. 2005;45: Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293: Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimuseluting stent: should we be cautious? Circulation. 2004;109: Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans. J Am Coll Cardiol. 2006;48: Mintz GS, Weissman NJ. Intravascular ultrasound in the DES era. J Am Coll Cardiol. 2006;48: Uren NG, Schwarzacher SP, Metz JA, Lee DP, Honda Y, Yeung AC, Fitzgerald PJ, Yock PG. Predictors and outcomes of stent thrombosis. Eur Heart J. 2002;23: Fujii K, Carlier SG, Mintz GS, Yang YM, Moussa I, Weisz G, Dangas G, Mehran R, Lansky AJ, Kreps EM, Collins M, Stone GW, Moses JW, Leon MB. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation. J Am Coll Cardiol. 2005;45: Windecker S, Remondino A, Eberli FR, Juni P, Raber L, Wenaweser P, Togni M, Billinger M, Tuller D, Seiler C, Roffi M, Corti R, Sutsch G, Maier W, Luscher T, Hess OM, Egger M, Meier B. Sirolimuseluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med. 2005;353: Kozuma K, Costa MA, Sabate M, Serrano P, van der Giessen WJ, Ligthart JM, Coen VL, Levendag PC, Serruys PW. Late stent malapposition occurring after intracoronary beta-irradiation detected by IVUS. J Invasive Cardiol. 1999;11: Cheneau E, Leborgne L, Mintz GS, Kotani J, Pichard AD, Satler LF, Canos D, Castagna M, Weissman NJ, Waksman R. Predictors of subacute stent thrombosis. Circulation. 2003;108: Mintz GS, Weissman NJ, Fitzgerald PJ. IVUS assessment of the mechanisms and results of brachytherapy. Circulation. 2001;104: Shah VM, Mintz GS, Apple S, Weissman NJ. Background incidence of late malapposition after BMS implantation. Circulation. 2002;106: Nakamura M, Kataoka T, Honda Y, Bonneau HN, Hibi K, Kitamura K, Tamai H, Aizawa T, Yock PG, Fitzgerald PJ. Late ISA and focal vessel expansion after bare metal stenting. Am J Cardiol. 2003;92: Hong MK, Mintz GS, Lee CW, Park DW, Park KM, Lee BK, Kim YH, Song JM, Han KH, Kang DH, Cheong SS, Song JK, Kim JJ, Park SW, Park SJ. Late stent malapposition after drug-eluting stent implantation. Circulation. 2006;113: Serruys PW, Degertekin M, Tanabe K, Abizaid A, Sousa JE, Colombo A, Guagliumi G, Wijns W, Lindeboom WK, Ligthart J, de Feyter PJ, Morice MC. IVUS findings in the multicenter, randomized, double-blind RAVEL trial. Circulation. 2002;106: Mintz GS, Shah VM, Weissman NJ. Regional remodeling as the cause of late stent malapposition. Circulation. 2003;107:

9 2434 Circulation May 8, Tanabe K, Serruys PW, Degertekin M, Grube E, Guagliumi G, Urbaszek W, Bonnier J, Lablanche JM, Siminiak T, Nordrehaug J, Figulla H, Drzewiecki J, Banning A, Hauptmann K, Dudek D, Bruining N, Hamers R, Hoye A, Ligthart JM, Disco C, Koglin J, Russell ME, Colombo A. Incomplete stent apposition after implantation of PES or BMS. Circulation. 2005;111: Ako J, Morino Y, Honda Y, Hassan A, Sonoda S, Yock PG, Leon MB, Moses JW, Bonneau HN, Fitzgerald PJ. Late incomplete stent apposition after sirolimuseluting stent implantation. J Am Coll Cardiol. 2005;46: Feres F, Costa JR Jr, Abizaid A. Very late thrombosis after drugeluting stents. Catheter Cardiovasc Interv. 2006;68: Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J, Davidson CJ, McKoy JM, Raisch DW, Whisenant BK, Yarnold PR, Belknap SM, West DP, Gage JE, Morse RE, Gligoric G, Davidson L, Feldman MD. Hypersensitivity cases associated with DES. J Am Coll Cardiol. 2006;47: Hong MK, Mintz GS, Lee CW, Kim YH, Lee SW, Song JM, Han KH, Kang DH, Song JK, Kim JJ, Park SW, Park SJ. Incidence, mechanism, predictors, and long-term prognosis of late ISA after BMS implantation. Circulation. 2004;109: Waksman R. Late thrombosis after radiation. Circulation. 1999;100: CLINICAL PERSPECTIVE Stent thrombosis is an infrequent but severe complication resulting in abrupt coronary artery closure, which may lead to myocardial infarction or sudden cardiac death. It may occur unusually late after drug-eluting stent implantation, and its cause is largely unknown. The present study sought to identify structural differences of the stented segment between patients with and without very late stent thrombosis ( 1 year) with the use of intravascular ultrasound. Findings in 13 patients with very late stent thrombosis were compared with intravascular ultrasound routinely obtained 8 months after drug-eluting stent implantation in 144 control patients, who did not experience stent thrombosis for 2 years. We observed a high prevalence of incomplete stent apposition in patients with very late stent thrombosis (77%) compared with drug-eluting stent controls (12%; P 0.001), suggesting a role in the pathogenesis of this adverse event. Several mechanisms of incomplete stent apposition have been proposed, including positive arterial remodeling, a decrease in plaque and media due to dissolution of jailed thrombus, persistent incomplete stent apposition, and chronic stent recoil. The first 2 mechanisms are most likely responsible for late acquired incomplete stent apposition complicating the use of drug-eluting stents.

Frequency and Characteristics of Incomplete Stent Apposition During and After Sirolimus-Eluting Stent Implantation

Frequency and Characteristics of Incomplete Stent Apposition During and After Sirolimus-Eluting Stent Implantation J Cardiol 2007 Aug; 50 2 : 111 118 Frequency and Characteristics of Incomplete Stent Apposition During and After Sirolimus-Eluting Stent Implantation Hiroki Yoshihiro Daisuke Tadashi Yota Naoko Nami Masakazu

More information

Sirolimus-Eluting Stents for Treatment of In-Stent Restenosis

Sirolimus-Eluting Stents for Treatment of In-Stent Restenosis Clinical Investigation Alfonso Medina, MD José Suárez de Lezo, MD Manuel Pan, MD Antonio Delgado, MD José Segura, MD Djordje Pavlovic, MD Francisco Melián, MD Miguel Romero, MD Federico Segura, MD Enrique

More information

Interventional Cardiology

Interventional Cardiology Interventional Cardiology Late Malapposition After Drug-Eluting Implantation An Intravascular Ultrasound Analysis With Long-Term Follow-Up Myeong-Ki Hong, MD, PhD; Gary S. Mintz, MD; Cheol Whan Lee, MD,

More information

Intravascular Ultrasound in the Drug-Eluting Stent Era

Intravascular Ultrasound in the Drug-Eluting Stent Era Journal of the American College of Cardiology Vol. 48, No. 3, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.04.068

More information

Stent Malapposition After Sirolimus-Eluting and Bare-Metal Stent Implantation in Patients with ST-Segment Elevation Myocardial Infarction

Stent Malapposition After Sirolimus-Eluting and Bare-Metal Stent Implantation in Patients with ST-Segment Elevation Myocardial Infarction JACC: CARDIOVASCULAR INTERVENTIONS VOL. 1, NO. 2, 2008 2008 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/08/$34.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2008.02.003 Stent Malapposition

More information

Intravascular Ultrasound Assessment of Drug-Eluting Stent Coverage of the Coronary Ostium and Effect on Outcomes

Intravascular Ultrasound Assessment of Drug-Eluting Stent Coverage of the Coronary Ostium and Effect on Outcomes Intravascular Ultrasound Assessment of Drug-Eluting Stent Coverage of the Coronary Ostium and Effect on Outcomes Soo-Jin Kang, MD, PhD a, Jung-Min Ahn, MD a, Won-Jang Kim, MD a, Jong-Young Lee, MD a, Duk-Woo

More information

Journal of the American College of Cardiology Vol. 46, No. 5, by the American College of Cardiology Foundation ISSN /05/$30.

Journal of the American College of Cardiology Vol. 46, No. 5, by the American College of Cardiology Foundation ISSN /05/$30. Journal of the American College of Cardiology Vol. 46, No. 5, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.06.009

More information

Late and Very Late Drug-Eluting Stent Malapposition Serial 2-Year Quantitative IVUS Analysis

Late and Very Late Drug-Eluting Stent Malapposition Serial 2-Year Quantitative IVUS Analysis Late and Very Late Drug-Eluting Stent Malapposition Serial 2-Year Quantitative IVUS Analysis Soo-Jin Kang, MD; Gary S. Mintz, MD; Duk-Woo Park, MD; Seung-Whan Lee, MD; Young-Hak Kim, MD; Cheol Whan Lee,

More information

A Volumetric Intravascular Ultrasound Comparison of Early Drug-Eluting Stent Thrombosis Versus Restenosis

A Volumetric Intravascular Ultrasound Comparison of Early Drug-Eluting Stent Thrombosis Versus Restenosis JACC: CARDIOVASCULAR INTERVENTIONS VOL. 2, NO. 5, 2009 2009 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/09/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2009.01.011 A Volumetric

More information

Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo

Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991

More information

Restenosis after implantation of sirolimus-eluting stent begins suddenly, shows short term progression, and stops suddenly

Restenosis after implantation of sirolimus-eluting stent begins suddenly, shows short term progression, and stops suddenly Journal of Cardiology (2011) 58, 26 31 a va i la b le at www.sciencedirect.com jo ur nal home page: www.elsevier.com/locate/jjcc Original article Restenosis after implantation of sirolimus-eluting stent

More information

journal of medicine The new england Sirolimus-Eluting and Paclitaxel-Eluting Stents for Coronary Revascularization abstract

journal of medicine The new england Sirolimus-Eluting and Paclitaxel-Eluting Stents for Coronary Revascularization abstract The new england journal of medicine established in 1812 august 18, 2005 vol. 353 no. 7 Sirolimus-Eluting and Paclitaxel-Eluting Stents for Coronary Revascularization Stephan Windecker, M.D., Andrea Remondino,

More information

Formation of and countermeasures for subacute coronary stent thrombosis in elderly diabetic patients

Formation of and countermeasures for subacute coronary stent thrombosis in elderly diabetic patients Formation of and countermeasures for subacute coronary stent thrombosis in elderly diabetic patients Z.-F. Li 1, Y.-P. Zhang 2, Z.-Q. Qin 2, X.-L. Li 1, C.-H. Gao 1, S. Yang 1 and Z.-J. Chen 1 1 Department

More information

Very late thrombosis of sirolimus-eluting stent due to late malapposition: Serial observations with optical coherence tomography

Very late thrombosis of sirolimus-eluting stent due to late malapposition: Serial observations with optical coherence tomography Journal of Cardiology (2008) 52, 290 295 CASE REPORT Very late thrombosis of sirolimus-eluting stent due to late malapposition: Serial observations with optical coherence tomography Takahiro Sawada (MD),

More information

Journal of the American College of Cardiology Vol. 47, No. 7, by the American College of Cardiology Foundation ISSN /06/$32.

Journal of the American College of Cardiology Vol. 47, No. 7, by the American College of Cardiology Foundation ISSN /06/$32. Journal of the American College of Cardiology Vol. 47, No. 7, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.05.102

More information

DOI: /CIRCINTERVENTIONS

DOI: /CIRCINTERVENTIONS Comparison of Zotarolimus-Eluting Stents With Sirolimus-Eluting and Paclitaxel-Eluting Stents Intimal Hyperplasia and Vascular Changes Assessed by Volumetric Intravascular Ultrasound Analysis Soo-Jin Kang,

More information

PCI for Long Coronary Lesion

PCI for Long Coronary Lesion PCI for Long Coronary Lesion Shift of a General Idea with the Introduction of DES In the Bare Metal Stent Era Higher Restenosis Rate With Increasing Stent Length and Decreasing Stent Area Restenosis.6.4.2

More information

Stent Thrombosis: Patient, Procedural, and Stent Factors. Eugene Mc Fadden Cork, Ireland

Stent Thrombosis: Patient, Procedural, and Stent Factors. Eugene Mc Fadden Cork, Ireland Stent Thrombosis: Patient, Procedural, and Stent Factors Eugene Mc Fadden Cork, Ireland Definitions Early 1 yr TAXUS >6months CYPHER Incidence and Timing BMS Registry data

More information

IVUS vs FFR Debate: IVUS-Guided PCI

IVUS vs FFR Debate: IVUS-Guided PCI IVUS vs FFR Debate: IVUS-Guided PCI Gary S. Mintz, MD Cardiovascular Research Foundation New York, NY Disclosure Statement of Financial Interest Within the past 12 months, I have had a financial interest/arrangement

More information

Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial

Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators

More information

Chronic Arterial Responses to Overlapping Paclitaxel-Eluting Stents

Chronic Arterial Responses to Overlapping Paclitaxel-Eluting Stents JACC: CARDIOVASCULAR INTERVENTIONS VOL. 1, NO. 2, 2008 2008 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/08/$34.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2007.12.005 Chronic

More information

Review Article. Thrombosis After Implantation of Drug-Eluting Stents

Review Article. Thrombosis After Implantation of Drug-Eluting Stents Review Article Hellenic J Cardiol 47: 31-38, 2006 Thrombosis After Implantation of Drug-Eluting Stents IOANNIS IAKOVOU 1, ROXANA MEHRAN 2, GEORGE DANGAS 2 1 Army Hospital of Thessaloniki, Greece and Euromedica,

More information

Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome

Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome Hiroyuki Okura*, MD; Nobuya Matsushita**,MD Kenji Shimeno**, MD; Hiroyuki Yamaghishi**, MD Iku Toda**,

More information

PCI for In-Stent Restenosis. CardioVascular Research Foundation

PCI for In-Stent Restenosis. CardioVascular Research Foundation PCI for In-Stent Restenosis ISR of BMS Patterns of In-Stent Restenosis Pattern I : Focal Type IA: Articulation / Gap Type IB: Marginal Type IC: Focal body Type ID: Multifocal Pattern II,III,IV : Diffuse

More information

JACC: CARDIOVASCULAR INTERVENTIONS VOL. 2, NO. 5, PUBLISHED BY ELSEVIER INC. DOI: /j.jcin

JACC: CARDIOVASCULAR INTERVENTIONS VOL. 2, NO. 5, PUBLISHED BY ELSEVIER INC. DOI: /j.jcin JACC: CARDIOVASCULAR INTERVENTIONS VOL. 2, NO. 5, 2009 2009 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/09/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2009.01.012 Incomplete

More information

Although a feasible therapeutic alternative to bypass

Although a feasible therapeutic alternative to bypass Comprehensive Intravascular Ultrasound Assessment of Stent Area and Its Impact on Restenosis and Adverse Cardiac Events in 403 Patients With Unprotected Left Main Disease Soo-Jin Kang, MD, PhD; Jung-Min

More information

HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?

HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal? HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February 2014 Drug-eluting stents Are they all equal? Vassilis Spanos Interventional Cardiologist, As. Director 3 rd Cardiology Clinic Euroclinic

More information

Long-Term Outcome of Simultaneous Kissing Stenting Technique With Sirolimus-Eluting Stent for Large Bifurcation Coronary Lesions

Long-Term Outcome of Simultaneous Kissing Stenting Technique With Sirolimus-Eluting Stent for Large Bifurcation Coronary Lesions Catheterization and Cardiovascular Interventions 70:840 846 (2007) Long-Term Outcome of Simultaneous Kissing Stenting Technique With Sirolimus-Eluting Stent for Large Bifurcation Coronary Lesions Young-Hak

More information

DES In-stent Restenosis

DES In-stent Restenosis DES In-stent Restenosis Roxana Mehran, MD Columbia University Medical Center The Cardiovascular Research Foundation DES Restenosis Mechanisms Predictors Morphological patterns Therapy approach Mechanisms

More information

Results of the Washington Radiation for In-Stent Restenosis Trial for Long Lesions (Long WRIST) Studies

Results of the Washington Radiation for In-Stent Restenosis Trial for Long Lesions (Long WRIST) Studies Intracoronary Radiation Therapy Improves the Clinical and Angiographic Outcomes of Diffuse In-Stent Restenotic Lesions Results of the Washington Radiation for In-Stent Restenosis Trial for Long Lesions

More information

Impact of arterial injury on neointimal hyperplasia after implantation of drug-eluting stents in coronary arteries: an intravascular ultrasound study

Impact of arterial injury on neointimal hyperplasia after implantation of drug-eluting stents in coronary arteries: an intravascular ultrasound study Clinical research Impact of arterial injury on neointimal hyperplasia after implantation of drug-eluting stents in coronary arteries: an intravascular ultrasound study Parham Eshtehardi 1, MD; Stéphane

More information

Drug eluting stents From revolution to evolution. Current limitations

Drug eluting stents From revolution to evolution. Current limitations Drug eluting stents From revolution to evolution Current limitations Eric Eeckhout Centre Hospitalier Universitaire Vaudois Lausanne - Switzerland eric.eeckhout@chuv.ch Overview Historical perspective

More information

IVUS Assessment of the Mechanism of In-stent Restenosis? Gary S. Mintz, MD Cardiovascular Research Foundation

IVUS Assessment of the Mechanism of In-stent Restenosis? Gary S. Mintz, MD Cardiovascular Research Foundation IVUS Assessment of the Mechanism of In-stent Restenosis? Gary S. Mintz, MD Cardiovascular Research Foundation SURE Trial: Restenosis in non-stented lesions Average of the two image slices with the smallest

More information

Optical Coherence Tomography for Intracoronary Imaging

Optical Coherence Tomography for Intracoronary Imaging Optical Coherence Tomography for Intracoronary Imaging Lorenz Räber Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland

More information

Ch apter 7. (Late) Stent Malapposition in the BMS and DES Era

Ch apter 7. (Late) Stent Malapposition in the BMS and DES Era Ch apter 7 (Late) Stent Malapposition in the BMS and DES Era Jeffrey J.W. Verschuren, MD 1 ; Tarek A.N. Ahmed, MD 1 ; Joannis Karalis, MD 1 ; Paul H.A. Quax, MD, PhD 2, 3 ; J.Wouter Jukema, MD, PhD 1,

More information

LM stenting - Cypher

LM stenting - Cypher LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with

More information

Original paper. Introduction. Material and methods. Aim

Original paper. Introduction. Material and methods. Aim Original paper Relation between coronary plaque calcium deposits as described by computed tomography coronary angiography and acute results of stent deployment as assessed by intravascular ultrasound Jerzy

More information

OCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis?

OCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis? OCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis? Juan F. Granada, MD Medical Director, Skirball Center for Cardiovascular Research

More information

Late Stent Thrombosis Following Implantation of a Drug Eluting Stent Presenting as Acute Myocardial Infarction: A Case Report

Late Stent Thrombosis Following Implantation of a Drug Eluting Stent Presenting as Acute Myocardial Infarction: A Case Report ISPUB.COM The Internet Journal of Cardiology Volume 4 Number 1 Late Stent Thrombosis Following Implantation of a Drug Eluting Stent Presenting as Acute Myocardial Infarction: A Case Report C Sarat, K Ritesh

More information

Drug-eluting stents (DES) reduce the rate of restenosis and

Drug-eluting stents (DES) reduce the rate of restenosis and Original Articles Mechanisms of In-Stent Restenosis After Drug-Eluting Stent Implantation Intravascular Ultrasound Analysis Soo-Jin Kang, MD; Gary S. Mintz, MD; Duk-Woo Park, MD; Seung-Whan Lee, MD; Young-Hak

More information

Béla MERKELY MD, PhD, DSc, FESC. Stent thrombosis: patophysiology, predisposing factors, definition, classification, prevention and treatment

Béla MERKELY MD, PhD, DSc, FESC. Stent thrombosis: patophysiology, predisposing factors, definition, classification, prevention and treatment Semmelweis University Heart Center Budapest, Hungary Béla MERKELY MD, PhD, DSc, FESC Stent thrombosis: patophysiology, predisposing factors, definition, classification, prevention and treatment 10th Interventional

More information

Affiliation/Financial Relationship

Affiliation/Financial Relationship The Next ERA: COMBO Dual Therapy Stent The Unmet Need Roxana Mehran, MD Mount Sinai i School of Medicine i Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have

More information

FREQUENCY OF STENT THROMBOSIS FOLLOWING PERCUTANEOUS CORONARY INTERVENTION WITH BARE METAL VERSUS DRUG ELUTING STENTS

FREQUENCY OF STENT THROMBOSIS FOLLOWING PERCUTANEOUS CORONARY INTERVENTION WITH BARE METAL VERSUS DRUG ELUTING STENTS FREQUENCY OF STENT THROMBOSIS FOLLOWING PERCUTANEOUS CORONARY INTERVENTION WITH BARE METAL VERSUS DRUG ELUTING STENTS 9 MUHAMMAD FAROOQ SAEED, IJAZ AHMED, AHMAD NOUMAN Objectives: To compare the frequency

More information

2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center

2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center 2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium Does Lt Late Cth Catch up Exist Eiti in DES? : Quantitative Coronary Angiography Analysis Kyung Woo Park, MD Cardiovascular

More information

INDEX 1 INTRODUCTION DEVICE DESCRIPTION CLINICAL PROGRAM FIRST-IN-MAN CLINICAL INVESTIGATION OF THE AMAZONIA SIR STENT...

INDEX 1 INTRODUCTION DEVICE DESCRIPTION CLINICAL PROGRAM FIRST-IN-MAN CLINICAL INVESTIGATION OF THE AMAZONIA SIR STENT... May 2017 INDEX 1 INTRODUCTION... 2 2 DEVICE DESCRIPTION... 3 ANTI-PROLIFERATIVE DRUG - SIROLIMUS... 3 BIODEGRADABLE POLYMERS... 3 SIROLIMUS CONTROLLED ELUTION... 4 STENT PLATFORM... 4 3 CLINICAL PROGRAM...

More information

The Site of Plaque Rupture in Native Coronary Arteries

The Site of Plaque Rupture in Native Coronary Arteries Journal of the American College of Cardiology Vol. 46, No. 2, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.03.067

More information

Intravascular Ultrasound Predictors for Edge Restenosis After Newer Generation Drug-Eluting Stent Implantation

Intravascular Ultrasound Predictors for Edge Restenosis After Newer Generation Drug-Eluting Stent Implantation Intravascular Ultrasound Predictors for Edge After Newer Generation Drug-Eluting Stent Implantation Soo-Jin Kang, MD, PhD a, Young-Rak Cho, MD a, Gyung-Min Park, MD a, Jung-Min Ahn, MD a, Won-Jang Kim,

More information

MULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION

MULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION MULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION C. Graidis, D. Dimitriadis, A. Ntatsios, V. Karasavvides Euromedica Kyanous Stavros, Thessaloniki.

More information

Neointimal coverage of bare-metal and sirolimuseluting stents evaluated with optical coherence tomography

Neointimal coverage of bare-metal and sirolimuseluting stents evaluated with optical coherence tomography Neointimal coverage of bare-metal and sirolimuseluting stents evaluated with optical coherence tomography B X Chen, F Y Ma, W Luo, J H Ruan, W L Xie, X Z Zhao, S H Sun, X M Guo, F Wang, T Tian, X W Chu

More information

Declaration of conflict of interest. Nothing to disclose

Declaration of conflict of interest. Nothing to disclose Declaration of conflict of interest Nothing to disclose Hong-Seok Lim, Seung-Jea Tahk, Hyoung-Mo Yang, Jin-Woo Kim, Kyoung- Woo Seo, Byoung-Joo Choi, So-Yeon Choi, Myeong-Ho Yoon, Gyo-Seung Hwang, Joon-Han

More information

Research Article Pathological Perspective of Drug-Eluting Stent Thrombosis

Research Article Pathological Perspective of Drug-Eluting Stent Thrombosis Thrombosis Volume 2012, Article ID 219389, 8 pages doi:10.1155/2012/219389 Research Article Pathological Perspective of Drug-Eluting Stent Thrombosis Katsumi Inoue Department of Laboratory Medicine, Kokura

More information

For Personal Use. Copyright HMP 2013

For Personal Use. Copyright HMP 2013 Case Report J INVASIVE CARDIOL 2013;25(2):E39-E41 A Case With Successful Retrograde Stent Delivery via AC Branch for Tortuous Right Coronary Artery Yoshiki Uehara, MD, PhD, Mitsuyuki Shimizu, MD, PhD,

More information

Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents

Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents J-S Kim, 1 I-K Jang, 2 J-S Kim, 1 T H Kim, 1 M Takano, 3 T Kume, 4 N

More information

OCT Findings: Lesson from Stable vs Unstable Plaques

OCT Findings: Lesson from Stable vs Unstable Plaques ANGIOPLASTY SUMMIT TCTAP 2010 Imaging Workshop OCT Findings: Lesson from Stable vs Unstable Plaques Giulio Guagliumi MD Ospedali Riuniti di Bergamo, Italy DISCLOSURE OF FINANCIAL INTERESTS Consultant Boston

More information

Frequency of and Risk Factors for Stent Thrombosis After Drug-Eluting Stent Implantation During Long-Term Follow-Up

Frequency of and Risk Factors for Stent Thrombosis After Drug-Eluting Stent Implantation During Long-Term Follow-Up Frequency of and Risk Factors for Stent Thrombosis After Drug-Eluting Stent Implantation During Long-Term Follow-Up Duk-Woo Park, MD, Seong-Wook Park, MD, PhD*, Kyoung-Ha Park, MD, Bong-Ki Lee, MD, Young-Hak

More information

Rationale for Percutaneous Revascularization ESC 2011

Rationale for Percutaneous Revascularization ESC 2011 Rationale for Percutaneous Revascularization Marie Claude Morice, Massy FR MD, FESC, FACC ESC 2011 Paris Villepinte - 27-31 August, 2011 Massy, France Potential conflicts of interest I have the following

More information

Catch-up Phenomenon: Insights from Pathology

Catch-up Phenomenon: Insights from Pathology Catch-up Phenomenon: Insights from Pathology Michael Joner, MD CVPath Institute Inc. Gaithersburg, MD USA Path Lessons learned from the BMS and DES (1 st Gen) era Neointimal Thickness [mm] In Stent Re

More information

Journal of the American College of Cardiology Vol. 47, No. 8, by the American College of Cardiology Foundation ISSN /06/$32.

Journal of the American College of Cardiology Vol. 47, No. 8, by the American College of Cardiology Foundation ISSN /06/$32. Journal of the American College of Cardiology Vol. 47, No. 8, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.11.066

More information

Unprotected LM intervention

Unprotected LM intervention Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline

More information

Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting Stents JAMA. 2005;293:

Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting Stents JAMA. 2005;293: BRIEF REPORT Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting Stents Ioannis Iakovou, MD Thomas Schmidt, MD Erminio Bonizzoni, PhD Lei Ge, MD Giuseppe M. Sangiorgi,

More information

COMPARISON OF BARE METAL VERSUS DRUG ELUTING STENTS

COMPARISON OF BARE METAL VERSUS DRUG ELUTING STENTS wjpmr, 2018,4(12), 334-340 SJIF Impact Factor: 4.639 Research Article WORLD JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH ISSN 2455-3301 www.wjpmr.com WJPMR COMPARISON OF BARE METAL VERSUS DRUG ELUTING

More information

Key Words Angioplasty Coronary artery disease Revascularization Stent drug eluting stent

Key Words Angioplasty Coronary artery disease Revascularization Stent drug eluting stent J Cardiol 26 Dec; 48 6 : 325 331 3 mm : Initial and Mid-Term Effects of 3 mm Long Sirolimus-Eluting Stents in Patients With Diffuse Long Coronary Lesions: Comparison With Bare Metal Stents Abstract Yosuke

More information

Lesions at coronary bifurcations represent a challenging

Lesions at coronary bifurcations represent a challenging Randomized Study to Evaluate Sirolimus-Eluting Stents Implanted at Coronary Bifurcation Lesions Antonio Colombo, MD; Jeffrey W. Moses, MD; Marie Claude Morice, MD; Josef Ludwig, MD; David R. Holmes, Jr,

More information

Bifurcation stenting with BVS

Bifurcation stenting with BVS Bifurcation stenting with BVS Breaking the limits or just breaking the struts? Maciej Lesiak Department of Cardiology University Hospital in Poznan, Poland Disclosure Speaker s name: Maciej Lesiak I have

More information

The Effect of Cilostazol on Stent Thrombosis After Drug-Eluting Stent Implantation

The Effect of Cilostazol on Stent Thrombosis After Drug-Eluting Stent Implantation ORIGINAL ARTICLE DOI 10.4070 / kcj.2010.40.1.10 Print ISSN 1738-5520 / On-line ISSN 1738-5555 Copyright c 2010 The Korean Society of Cardiology Open Access The Effect of Cilostazol on Stent Thrombosis

More information

Next Generation Drug- eluting Stent : Will It Solve the Problem?

Next Generation Drug- eluting Stent : Will It Solve the Problem? Next Generation Drug- eluting Stent : Will It Solve the Problem? Yangsoo Jang, M.D., Ph.D, FACC Severance Cardiovascular Hospital Yonsei University Healthcare System Commercially Available DES An Epidemic

More information

Bern-Rotterdam Cohort Study

Bern-Rotterdam Cohort Study Bern-Rotterdam Cohort Study Newer generation everolimus-eluting stents eliminate the risk of very late stent thrombosis compared with early generation sirolimus-eluting and paclitaxel-eluting stents Lorenz

More information

Left main coronary artery (LMCA): The proximal segment

Left main coronary artery (LMCA): The proximal segment Anatomy and Pathology of Left main coronary artery G Nakazawa Tokai Univ. Kanagawa, Japan 1 Anatomy Difinition Left main coronary artery (LMCA): The proximal segment RCA AV LAD LM LCX of the left coronary

More information

For Personal Use. Copyright HMP 2014

For Personal Use. Copyright HMP 2014 Original Contribution Long-Term Safety and Efficacy of the Everolimus-Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice Israel M. Barbash, MD, Sa ar Minha,

More information

Clinical Investigations

Clinical Investigations Clinical Investigations Clinical Outcomes for Single Stent and Multiple Stents in Contemporary Practice Qiao Shu Bin, MD; Liu Sheng Wen, MD; Xu Bo, BS; Chen Jue, MD; Liu Hai Bo, MD; Yang Yue Jin, MD; Chen

More information

IVUS Analysis. Myeong-Ki. Hong, MD, PhD. Cardiac Center, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea

IVUS Analysis. Myeong-Ki. Hong, MD, PhD. Cardiac Center, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea IVUS Analysis Myeong-Ki Hong, MD, PhD Cardiac Center, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea Intimal disease (plaque) is dense and will appear white Media is made of

More information

Acta Cardiol Sin 2018;34: doi: /ACS _34(2) A

Acta Cardiol Sin 2018;34: doi: /ACS _34(2) A Original Article Acta Cardiol Sin 2018;34:124 129 doi: 10.6515/ACS.201803_34(2).20171115A Coronary Artery Disease Vascular Healing Response after Everolimus-Eluting Stent Implantation in Acute Coronary

More information

A Fatal Case of Simultaneous, Very Late Thrombosis Involving Three Drug-Eluting Stents in Three Coronary Arteries

A Fatal Case of Simultaneous, Very Late Thrombosis Involving Three Drug-Eluting Stents in Three Coronary Arteries CASE REPORT Korean Circ J 2008;38:564-569 Print ISSN 1738-5520 / On-line ISSN 1738-5555 Copyright c 2008 The Korean Society of Cardiology A Fatal Case of Simultaneous, Very Late Thrombosis Involving Three

More information

in an Unyielding Patient Dr Jason See, Dr Goh Yew Seong, Dr Rohit Khurana Changi General Hospital Singapore

in an Unyielding Patient Dr Jason See, Dr Goh Yew Seong, Dr Rohit Khurana Changi General Hospital Singapore Unrelenting Left Main Disease in an Unyielding Patient Dr Jason See, Dr Goh Yew Seong, Dr Rohit Khurana Changi General Hospital Singapore Clinical History 72 years old Chinese lady Background and CV Risk

More information

TO ASSESS THE ADEQUACY OF CORONARY STENTS DEPLOYMENT (APPOSITION)WITH INTRAVASCULAR ULTRASOUND IN COMPARISON WITH CORONARY ANGIOGRAPHY

TO ASSESS THE ADEQUACY OF CORONARY STENTS DEPLOYMENT (APPOSITION)WITH INTRAVASCULAR ULTRASOUND IN COMPARISON WITH CORONARY ANGIOGRAPHY ORIGINAL ARTICLE TO ASSESS THE ADEQUACY OF CORONARY STENTS DEPLOYMENT (APPOSITION)WITH INTRAVASCULAR ULTRASOUND IN COMPARISON WITH CORONARY ANGIOGRAPHY 1 2 3 4 Iftikhar Ahmad Khan, Jabar Ali, Abdul Wali

More information

PCI for Left Anterior Descending Artery Ostial Stenosis

PCI for Left Anterior Descending Artery Ostial Stenosis PCI for Left Anterior Descending Artery Ostial Stenosis Why do you hesitate PCI for LAD ostial stenosis? LAD Ostial Lesion Limitations of PCI High elastic recoil Involvement of the distal left main coronary

More information

DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.

DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea. DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea. In-stent restenosis (ISR) Remains important issue even in the

More information

Basics of Angiographic Interpretation Analysis of Angiography

Basics of Angiographic Interpretation Analysis of Angiography Basics of Angiographic Interpretation Analysis of Angiography Young-Hak Kim, MD, PhD Cardiac Center, University of Ulsan College of Medicine, Seoul, Korea What made us nervous Supervisors Stent Contrast

More information

Abstract Background: Methods: Results: Conclusions:

Abstract Background: Methods: Results: Conclusions: Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li

More information

Cutting-balloon angioplasty before drug-eluting stent implantation for the treatment of severely calcified coronary lesions

Cutting-balloon angioplasty before drug-eluting stent implantation for the treatment of severely calcified coronary lesions Journal of Geriatric Cardiology (2014) 11: 44 49 2014 JGC All rights reserved; www.jgc301.com Research Article Open Access Cutting-balloon angioplasty before drug-eluting stent implantation for the treatment

More information

Stent Thrombosis in Bifurcation Stenting

Stent Thrombosis in Bifurcation Stenting Summit TCT Asia Pacific 2009 Stent Thrombosis in Bifurcation Stenting Associate Professor Tan Huay Cheem MBBS, M Med(Int Med), MRCP, FRCP(UK), FAMS, FACC, FSCAI Director, National University Heart Centre,

More information

In-Stent Restenosis. Can we kill it?

In-Stent Restenosis. Can we kill it? In-Stent Restenosis Can we kill it? However, In-stent Restenosis is the most serious problem (2-25%) More than 15, lesions will need treatment because of in-stent restenosis. Varying Prevalence Rates of

More information

Incidence and predictors of drug-eluting stent fractures in long coronary disease

Incidence and predictors of drug-eluting stent fractures in long coronary disease International Journal of Cardiology 133 (2009) 354 358 www.elsevier.com/locate/ijcard Incidence and predictors of drug-eluting stent fractures in long coronary disease Hyun-Sook Kim a, Young-Hak Kim b,

More information

Effectiveness of Paclitaxel-Eluting Balloon Catheter in Patients With Sirolimus-Eluting Stent Restenosis

Effectiveness of Paclitaxel-Eluting Balloon Catheter in Patients With Sirolimus-Eluting Stent Restenosis JACC: CARDIOVASCULAR INTERVENTIONS VOL. 4, NO. 2, 2011 2011 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2010.10.012 CLINICAL RESEARCH

More information

STENTYS for Le, Main Sten2ng. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy

STENTYS for Le, Main Sten2ng. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy STENTYS for Le, Main Sten2ng Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy Disclosure Statement of Financial Interest I, Carlo Briguori DO NOT have a financial interest/ arrangement or affilia2on

More information

Pathology of percutaneous interventions (PCI) in coronary arteries. Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL

Pathology of percutaneous interventions (PCI) in coronary arteries. Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL Pathology of percutaneous interventions (PCI) in coronary arteries Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL Percutaneous Coronary Intervention (PCI) Definition: transcatheter opening of

More information

Journal of the American College of Cardiology Vol. 47, No. 3, by the American College of Cardiology Foundation ISSN /06/$32.

Journal of the American College of Cardiology Vol. 47, No. 3, by the American College of Cardiology Foundation ISSN /06/$32. Journal of the American College of Cardiology Vol. 47, No. 3, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.09.040

More information

TLR des Stents Actifs

TLR des Stents Actifs TLR des Stents Actifs No Conflict of Interest Target Lesion Revascularization DES vs BMS Stettler C et al. Lancet 2007;370:937-48 N=18,023 58% 70% SES vs BMS: HR=0.30 (0.24-0.37), p

More information

Impact of Positive Peri-Stent Vascular Remodeling After Sirolimus-Eluting and Paclitaxel-Eluting Stent Implantation on 5-Year Clinical Outcomes

Impact of Positive Peri-Stent Vascular Remodeling After Sirolimus-Eluting and Paclitaxel-Eluting Stent Implantation on 5-Year Clinical Outcomes Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp ORIGINAL ARTICLE Cardiovascular Intervention Impact of Positive Peri-Stent Vascular Remodeling After Sirolimus-Eluting

More information

Temporal Relation Between Clopidogrel Cessation and Stent Thrombosis After Drug-Eluting Stent Implantation

Temporal Relation Between Clopidogrel Cessation and Stent Thrombosis After Drug-Eluting Stent Implantation Temporal Relation Between Clopidogrel Cessation and Stent Thrombosis After Drug-Eluting Stent Implantation Probal Roy, MD, Laurent Bonello, MD, Rebecca Torguson, MPH, Teruo Okabe, MD, Tina L. Pinto Slottow,

More information

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main

More information

Firebird stent for the treatment of patients with coronary heart disease: short-term clinical outcome

Firebird stent for the treatment of patients with coronary heart disease: short-term clinical outcome Journal of Geriatric Cardiology September 2009 Vol 6 No 3 157 Clinical Research Firebird stent for the treatment of patients with coronary heart disease: short-term clinical outcome Hai-Ying Wang, 1 Jin-Bo

More information

Le# main treatment with Stentys stent. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy

Le# main treatment with Stentys stent. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy Le# main treatment with Stentys stent Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy Disclosure Statement of Financial Interest I, Carlo Briguori DO NOT have a financial interest/ arrangement

More information

Post PCI functional testing and imaging: case based lessons from FFR React

Post PCI functional testing and imaging: case based lessons from FFR React Post PCI functional testing and imaging: case based lessons from FFR React Joost Daemen, MD, PhD, FESC Optics in Cardiology 2018 April 21st, 2018 10.15 10.30h Disclosure Statement of Financial Interest

More information

PROMUS Element Experience In AMC

PROMUS Element Experience In AMC Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical

More information

Acute and Subacute Stent Thrombosis in a Patient With Clopidogrel Resistance: A Case Report

Acute and Subacute Stent Thrombosis in a Patient With Clopidogrel Resistance: A Case Report CSE REPORT DOI 10.4070 / kcj.2009.39.10.434 Print ISSN 1738-5520 / On-line ISSN 1738-5555 Copyright c 2009 The Korean Society of Cardiology Open ccess cute and Subacute Stent Thrombosis in a Patient With

More information

Journal of the American College of Cardiology Vol. 51, No. 6, by the American College of Cardiology Foundation ISSN /08/$34.

Journal of the American College of Cardiology Vol. 51, No. 6, by the American College of Cardiology Foundation ISSN /08/$34. Journal of the American College of Cardiology Vol. 51, No. 6, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.09.056

More information